Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Company Overview

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation. Its diverse pipeline includes antibody-based constructs and small-molecule inhibitors targeting both solid tumors and hematologic malignancies. Preclinical data have demonstrated promising anti-tumor activity and favorable safety profiles, supporting the advancement of several programs toward first-in-human studies.

Headquartered in Massachusetts, Rapport Therapeutics collaborates with academic institutions, contract research organizations and industry partners to drive its research and development efforts. The company is led by a management team with extensive experience in oncology drug development, clinical operations and regulatory strategy. With a strategic focus on translating scientific insights into innovative cancer therapies, Rapport aims to improve outcomes for patients worldwide.

Key Stats

• Today's Range: $14.21 to $16.00
• 50-Day Range: $11.31 to $17.63
• 52-Week Range: $6.43 to $29.74
• Volume: 371,868 shs
• Average Volume: 216,110 shs
• Market Capitalization: $524.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.50
• Consensus Rating: Buy

Rapport Therapeutics Stock Analysis - MarketRank™

Rapport Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 576th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Rapport Therapeutics has a consensus price target of $29.50, representing about 105.4% upside from its current price of $14.36.

Amount of Analyst Coverage

Rapport Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rapport Therapeutics is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rapport Therapeutics is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rapport Therapeutics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.30% of the float of Rapport Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rapport Therapeutics has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Rapport Therapeutics has recently decreased by 0.98%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rapport Therapeutics does not currently pay a dividend.

Dividend Growth

Rapport Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.30% of the float of Rapport Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rapport Therapeutics has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Rapport Therapeutics has recently decreased by 0.98%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.92

News Sentiment

Rapport Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rapport Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $365,500.00 in company stock.

Percentage Held by Insiders

13.57% of the stock of Rapport Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

RAPP Stock Analysis - Frequently Asked Questions

How have RAPP shares performed this year?

Rapport Therapeutics' stock was trading at $17.74 at the beginning of the year. Since then, RAPP shares have decreased by 19.1% and is now trading at $14.36.

How were Rapport Therapeutics' earnings last quarter?

Rapport Therapeutics, Inc. (NASDAQ:RAPP) released its earnings results on Thursday, August, 7th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.12.

When did Rapport Therapeutics IPO?

Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at $17.00 per share.

Who are Rapport Therapeutics' major shareholders?

Top institutional investors of Rapport Therapeutics include Alliancebernstein L.P. (3.16%), Geode Capital Management LLC (0.91%), Affinity Asset Advisors LLC (0.55%) and TD Asset Management Inc (0.54%). Insiders that own company stock include David Bredt, James Healy, Troy A Ignelzi and Wendy B Young.
View institutional ownership trends.

How do I buy shares of Rapport Therapeutics?

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rapport Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Biopartners (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RAPP
• Previous Symbol: NASDAQ:RAPP
• CIK: 2012593
• Web: N/A
• Phone: (857) 321-8020
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rapport Therapeutics: $29.50
• High Price Target: $31.00
• Low Price Target: $28.00
• Potential Upside/Downside: +105.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.99%
• Return on Assets: -28.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.75
• Quick Ratio: 22.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.35 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 36,500,000
• Free Float: 31,545,000
• Market Cap: $524.14 million
• Optionable: N/A
• Beta: 0.71